2 results
Approved WMOWill not start
Phase 2: To evaluate progression-free survival (PFS) as the primary efficacy measure of MLN1117 plus docetaxel versus docetaxel alone in patients with advanced NSCLC
Approved WMOPending
Dividing the study population in four categories (oncological patients, critically ill patients admitted to intensive care, neonates and other children) answers to the following questions are sought:- which initial dosage regimen for vancomycin…